lundi 28 août 2017

Onco Actu du 28 août 2017

1. Biologie

A Cancer “Atlas” to Predict How Patients Will Fare [MIT Technology Review]

2.10 Etiologie - Alcool

Alcohol linked to an increased risk of skin cancer [NHS Choices]

3.1 Tabac

Philip Morris International CEO cheers U.S. FDA tobacco proposal [Reuters]

BAT's $25 Billion Lucky Strike [Bloomberg]

3.1.1 Tabac - e-cigs

Teens who vape might be more likely to try cigarettes, study suggests [Cancer Research UK]

Study of e-cigarettes in UK teenagers gives mixed signals [Reuters]

FDA to expand public education campaign to focus on prevention of youth e-cigarette use [FDA]

FDA to launch campaign against e-cigarette use among youth [Reuters]

3.2 Prévention - Obésité

The UK’s pick ‘n’ mix approach to children’s obesity is missing a trick [cancer Research UK]

3.3 Prévention - Vaccins

HPV Vaccination Rates Especially Low Among Childhood Cancer Survivors [ASCO]

3.5 Prévention - UV

The ‘Tanning Tax’ Is A Public Health Success Story [Health Affairs Blog]

3.8 Prévention - Alimentation

'Junk food' may increase cancer risk in 'healthy weight' women [NHS Choices]

4. Dépistage, diagnostic et pronostic

The overdiagnosis community targets solutions [BMJ]

4.1 Dép., diag. & prono. - Prostate

New imaging technique spots prostate tumours starved of oxygen [Cancer Research UK]

Prostate cancer testing: has the bubble burst? [The Conversation]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Britain's Creo receives speedy FDA approval for its endoscopic device [Reuters]

4.12 Biopsies liquides

Can a ‘liquid biopsy’ detect cancer and save lives? [STAT]

Silicon Valley Startup Grail Sees Hope for Cancer Blood Test [Bloomberg]

Cancer Blood Tests Score Early Success [MIT Technology Review]

4.9 Dép., diag. & prono. - Sein

U.S. study revives argument over mammogram screening [Reuters]

For older breast cancer survivors, unclear when to stop mammograms [Reuters]

5. Traitements

Guideline on Stage IV Non-Small-Cell Lung Cancer Therapy Updated [ASCO]

Vitamin C injections could play a role in treating blood cancers [NHS Choices]

Drug Aimed at Inflammation May Lower Risk of Heart Disease and Cancer [NY Times]

5.10 Traitements - Essais

Biggest challenges of multi-region clinical trials identified [European Pharmaceutical Review]

5.12 Immunothérapies

Studies highlight ‘potential new targets for immunotherapy’ [Cancer Research UK]

NCI study identifies essential genes for cancer immunotherapy [NCI]

“First in Human” Documentary Highlights NCI Immunotherapy Research [NCI]

5.12.1 Immunothérapies - partenariats

Cancer Research UK and Biotecnol to trial new immuno-oncology treatment for advanced tumours [Cancer Research UK]

5.12.2 Immunothérapies - CAR-T

New CAR-T drug for leukemia, while effective, is ‘going to cost a fortune’ [STAT]

With CAR-T marketing looming, early study highlights potential of TCR engineering [EndPoints]

Kite Announces Initiation of Axicabtagene Ciloleucel CAR-T Clinical Program in the European Union [Kite]

5.12.3 Immunothérapies-combinaisons

Bristol-Myers puts up Opdivo-plus-Yervoy data, adding to combo-therapy mystery [FiercePharma]

Bristol-Myers Squibb Announces Topline Results from CheckMate -214, a Phase 3 Study of Opdivo in Combination with Yervoy in Intermediate and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma [BMS]

Bristol-Myers shares sink after another setback for its immuno-oncology franchise drugs [EndPoints]

5.12.5 Immunothérapies - Pharma

Juno executives investigated over trial deaths disclosure by law firm [FierceBiotech]

5.12.6 Immunothérapies - AMM

FDA Approves Nivolumab for Some Metastatic Colorectal Cancers [NCI]

5.2 Pharma

Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned [Novartis]

Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger [EndPoints]

After a long clinical odyssey, the FDA tapped this PhIII anti-CCR4 as a ‘breakthrough’ lymphoma drug [EndPoints]

An Also-Ran in Cancer Drugs, Sanofi Sees Chance to Close the Gap [Bloomberg]

5.2.2 Pharma - Fusions & Acquisitions

Gilead agrees to buy Kite Pharma, leaping into CAR-T cancer therapy [STAT]

Gilead Sciences to Acquire Kite Pharma for $11.9 Billion [Business Wire]

Gilead to Buy Kite Pharma for Roughly $11 Billion in Cash [Wall Street Journal]

5.2.3 Pharma - économie

Drug makers deserve to be publicly shamed for thwarting competition from generics [STAT]

New Novartis rival Kisqali hasn't slowed down Pfizer's Ibrance—at least not yet [FiercePharma]

5.3 Traitements - FDA, EMA, NICE...

Another Brick in the Wall: A New Commitment Implementing the Mutual Recognition of Inspections [FDA Law Blog]

Drug approval needs a helping hand [Nature]

5.3.4 Traitements - AMM (FDA, EMA)

Lynparza receives additional and broad approval in the US for ovarian cancer [AstraZeneca]

Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor [Novartis]

Pfizer Receives U.S. FDA Approval for BESPONSA® (inotuzumab ozogamicin) [Pfizer]

AVEO Oncology Announces FOTIVDA® (tivozanib) Approved in the European Union for the Treatment of Advanced Renal Cell Carcinoma [Aveo]

Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer [AstraZeneca]

FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia [FDA]

Novartis receives EU approval for breast cancer drug Kisqali [Reuters]

FDA expands use of AstraZeneca/Merck ovarian cancer drug [Reuters]

FDA approves Pfizer's drug for rare blood cancer [Reuters]

Pfizer’s CD22-targeted cancer drug inotuzumab wins an accelerated OK at FDA [EndPoints]

Bayer Receives EU Approval for Stivarga® (Regorafenib) for the Second-Line Systemic Treatment of Liver Cancer [Bayer]

5.4 Traitements - Economie

Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma [NICE]

NICE flip-flops on Takeda's Adcetris—with restrictions [FiercePharma]

Patients getting faster access to cancer drugs as NICE approves three quarters of the Cancer Drugs Fund [NICE]

6. Lutte contre les cancers

UT Nominates MD Anderson Alum Peter Pisters to Replace DePinho [Xconomy]

6.1 Observation

Heart Attack, Stroke Risk May Be Elevated Following Cancer Diagnosis [NCI]

More Young People Are Dying of Colon Cancer [NY Times]

Colorectal Cancer Death Rates Rising in People Under 55 [ACS]

Aggressive breast cancers may contribute to racial survival disparities [UNC]

6.5 Médecines alternatives

'Alternative cancer therapies' may increase your risk of death [NHS Choices]

Alternative medicine: Deadly for cancer patients [Respectful Insolence]

6.6 Publications

A bold open-access push in Germany could change the future of academic publishing [Science]

A long journey to reproducible results [Nature]

Thoughts on Reproducibility [In the Pipeline]

Half of papers searched for online are free to read [Nature]

6.7 DMP, Big Data & applis

The Fuzzy Factor: Striving to Protect Patient Privacy in Big Data Sets [Cancer Research Catalyst]

6.8 Communication

TIME’s ‘miracle cure’ coverage reflects common problems with cancer stories [HealthNewsReview]

Cancer treatment: sorting the good news from the hype [The Guardian]

6.9 Controverses

$417 Million Awarded in Suit Tying Johnson’s Baby Powder to Cancer [NY Times]